{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["ca51adf0-e4e1-4d94-8daf-84dee6969629", "Q2", 74556, "JAMES P. KEESE", 167498, "TEVA PHARMACEUTICALS USA", 2008, "second_quarter", "2008-07-16T09:53:54-04:00", 40000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/ca51adf0-e4e1-4d94-8daf-84dee6969629/\", \"filing_uuid\": \"ca51adf0-e4e1-4d94-8daf-84dee6969629\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2008, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/ca51adf0-e4e1-4d94-8daf-84dee6969629/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"40000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Kelly Maughan, Office Manager\", \"dt_posted\": \"2008-07-16T09:53:54-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"400 NORTH CAPITOL STREET NW\", \"registrant_address_2\": \"SUITE 585\", \"registrant_different_address\": false, \"registrant_city\": \"WASHINGTON\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20001\", \"registrant\": {\"id\": 74556, \"url\": \"https://lda.senate.gov/api/v1/registrants/74556/\", \"house_registrant_id\": 36042, \"name\": \"JAMES P. KEESE\", \"description\": \"Government Affairs Consulting\", \"address_1\": \"444 North Capitol Street, NW\", \"address_2\": \"Suite 840\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20001\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"SHANNON BAIRD\", \"contact_telephone\": \"+1 703-477-3310\", \"dt_updated\": \"2026-01-30T19:35:24.801281-05:00\"}, \"client\": {\"id\": 167498, \"url\": \"https://lda.senate.gov/api/v1/clients/167498/\", \"client_id\": 12, \"name\": \"TEVA PHARMACEUTICALS USA\", \"general_description\": null, \"client_government_entity\": false, \"client_self_select\": false, \"state\": \"PA\", \"state_display\": \"Pennsylvania\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"PA\", \"ppb_state_display\": \"Pennsylvania\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2007-08-06\"}, \"lobbying_activities\": [{\"general_issue_code\": \"CPT\", \"general_issue_code_display\": \"Copyright/Patent/Trademark\", \"description\": \"H.R. 1432 - Preserve Access to Affordable Generics Act, S. 316 - Preserve Access to Affordable Generics Act,H.R. 1908 - Patent Reform Act of 2007, S. 1145 - Patent Reform Act of 2007, H.R. 1902 - Protecting Consumer Access to Generic Drugs Act\", \"foreign_entity_issues\": \"Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above\", \"lobbyists\": [{\"lobbyist\": {\"id\": 47013, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"P\", \"last_name\": \"KEESE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 64, \"name\": \"Federal Trade Commission (FTC)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 113, \"name\": \"Patent & Trademark Office (PTO)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 22, \"name\": \"U.S. Trade Representative (USTR)\"}]}, {\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"S. 623/Access to Life-Saving Medicine Act, S. 438/Fair Prescription Drug Competition Act, H.R. 806/Fair Prescription Drug Competition Act, H.R. 1956/Patient Protection and Innovative Biologic Medicines Act of 2007, H.R. 5629, H.R. 1038/Access to Life-Saving Medicine Act, S. 1505/Affordable Biologics for Consumers Act, S. 1695/Biologics Act of 2007, HR 3610\", \"foreign_entity_issues\": \"Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above\", \"lobbyists\": [{\"lobbyist\": {\"id\": 47013, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"P\", \"last_name\": \"KEESE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 64, \"name\": \"Federal Trade Commission (FTC)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 113, \"name\": \"Patent & Trademark Office (PTO)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 22, \"name\": \"U.S. Trade Representative (USTR)\"}]}, {\"general_issue_code\": \"TRD\", \"general_issue_code_display\": \"Trade (domestic/foreign)\", \"description\": \"Matters relating to Israeli data exclusivity, matters relating to pharmaceutical provisions in free trade agreements.\", \"foreign_entity_issues\": \"Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above\", \"lobbyists\": [{\"lobbyist\": {\"id\": 47013, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"P\", \"last_name\": \"KEESE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 64, \"name\": \"Federal Trade Commission (FTC)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 113, \"name\": \"Patent & Trademark Office (PTO)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 22, \"name\": \"U.S. Trade Representative (USTR)\"}]}, {\"general_issue_code\": \"MMM\", \"general_issue_code_display\": \"Medicare/Medicaid\", \"description\": \"S. 1951 - The Fair Medicaid Drug Payment Act of 2007\\nH.R. 3700 - The Fair Medicaid Drug Payment Act of 2007\\nH.R. 3140 - Saving Our Community Pharmacies Act of 2007\", \"foreign_entity_issues\": \"Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above\", \"lobbyists\": [{\"lobbyist\": {\"id\": 47013, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"P\", \"last_name\": \"KEESE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 64, \"name\": \"Federal Trade Commission (FTC)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 113, \"name\": \"Patent & Trademark Office (PTO)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 22, \"name\": \"U.S. Trade Representative (USTR)\"}]}, {\"general_issue_code\": \"BUD\", \"general_issue_code_display\": \"Budget/Appropriations\", \"description\": \"President Bush FY 2008 Budget Request - $15.7 million dollars Generic Drug User Fees.\\nMatters relating to FDA Office of Generic Drugs funding.\\nAgriculture Appropriations.\", \"foreign_entity_issues\": \"Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above\", \"lobbyists\": [{\"lobbyist\": {\"id\": 47013, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JAMES\", \"nickname\": null, \"middle_name\": \"P\", \"last_name\": \"KEESE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 136, \"name\": \"Centers For Medicare and Medicaid Services (CMS)\"}, {\"id\": 64, \"name\": \"Federal Trade Commission (FTC)\"}, {\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 113, \"name\": \"Patent & Trademark Office (PTO)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 22, \"name\": \"U.S. Trade Representative (USTR)\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["ca51adf0-e4e1-4d94-8daf-84dee6969629"], "units": {}, "query_ms": 3.0403491109609604, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}